Literature DB >> 15288255

Emerging classes of protein-protein interaction inhibitors and new tools for their development.

Len Pagliaro1, Jakob Felding, Karine Audouze, Søren Jensby Nielsen, Robert B Terry, Christian Krog-Jensen, Steven Butcher.   

Abstract

Protein-protein interactions play a key role in the signal transduction pathways that regulate cellular function. Three years ago, few descriptions of small molecule protein-protein interaction inhibitors (SMPPIIs) existed in the literature. Today, the number of examples of both the biology and chemistry of such interaction inhibitors is growing rapidly. This growth occurs at the convergence of medicinal chemistry, signaling biology and novel assay technology for profiling emerging compound classes and modes of action. Protein translocation assays provide a unique new tool for identifying, profiling, and optimizing SMPPIIs. This review summarizes recent work in the field, and outlines future developments we can anticipate.

Mesh:

Substances:

Year:  2004        PMID: 15288255     DOI: 10.1016/j.cbpa.2004.06.006

Source DB:  PubMed          Journal:  Curr Opin Chem Biol        ISSN: 1367-5931            Impact factor:   8.822


  45 in total

1.  Allosteric inhibition of the regulator of G protein signaling-Galpha protein-protein interaction by CCG-4986.

Authors:  David L Roman; Levi L Blazer; C Aaron Monroy; Richard R Neubig
Journal:  Mol Pharmacol       Date:  2010-06-07       Impact factor: 4.436

Review 2.  Evolution of immunity: no development without risk.

Authors:  Alexander B Sigalov
Journal:  Immunol Res       Date:  2012-06       Impact factor: 2.829

3.  Cells diversify transmembrane signaling through the controlled chaos of protein disorder.

Authors:  Alexander B Sigalov
Journal:  Self Nonself       Date:  2011-04-01

4.  Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2.

Authors:  Drew D Dudgeon; Sunita N Shinde; Tong Ying Shun; John S Lazo; Christopher J Strock; Kenneth A Giuliano; D Lansing Taylor; Patricia A Johnston; Paul A Johnston
Journal:  Assay Drug Dev Technol       Date:  2010-08       Impact factor: 1.738

Review 5.  Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma.

Authors:  Hayriye V Erkizan; Vladimir N Uversky; Jeffrey A Toretsky
Journal:  Clin Cancer Res       Date:  2010-06-14       Impact factor: 12.531

Review 6.  Targeting protein-protein interactions by rational design: mimicry of protein surfaces.

Authors:  Steven Fletcher; Andrew D Hamilton
Journal:  J R Soc Interface       Date:  2006-04-22       Impact factor: 4.118

Review 7.  G protein betagamma subunits as targets for small molecule therapeutic development.

Authors:  Alan V Smrcka; David M Lehmann; Axel L Dessal
Journal:  Comb Chem High Throughput Screen       Date:  2008-06       Impact factor: 1.339

8.  Multiplex assay for condition-dependent changes in protein-protein interactions.

Authors:  Ulrich Schlecht; Molly Miranda; Sundari Suresh; Ronald W Davis; Robert P St Onge
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

9.  2P2I HUNTER: a tool for filtering orthosteric protein-protein interaction modulators via a dedicated support vector machine.

Authors:  Véronique Hamon; Raphael Bourgeas; Pierre Ducrot; Isabelle Theret; Laura Xuereb; Marie Jeanne Basse; Jean Michel Brunel; Sebastien Combes; Xavier Morelli; Philippe Roche
Journal:  J R Soc Interface       Date:  2013-11-06       Impact factor: 4.118

Review 10.  Expanding the number of 'druggable' targets: non-enzymes and protein-protein interactions.

Authors:  Leah N Makley; Jason E Gestwicki
Journal:  Chem Biol Drug Des       Date:  2013-01       Impact factor: 2.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.